These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28622326)

  • 21. Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
    Glassman AR; Liu D; Jampol LM; Sun JK;
    Invest Ophthalmol Vis Sci; 2018 Mar; 59(3):1199-1205. PubMed ID: 29625440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
    Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
    Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Switching to eylea in macular edema due to retinal vascular diseases].
    Pascual-Camps I; Hernández-Martínez P; Ruiz J; Dolz-Marco R; Cuellar MJ; Gallego-Pinazo R
    Arch Soc Esp Oftalmol; 2015 Jan; 90(1):48. PubMed ID: 25200895
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
    Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
    Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ziv-aflibercept in macular disease.
    Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
    Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
    Wykoff CC; Ou WC; Khurana RN; Brown DM; Lloyd Clark W; Boyer DS;
    Br J Ophthalmol; 2018 May; 102(5):631-636. PubMed ID: 28814412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
    ; Wells JA; Glassman AR; Ayala AR; Jampol LM; Aiello LP; Antoszyk AN; Arnold-Bush B; Baker CW; Bressler NM; Browning DJ; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW
    N Engl J Med; 2015 Mar; 372(13):1193-203. PubMed ID: 25692915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients.
    Ruiz-Moreno JM; de Andrés-Nogales F; Oyagüez I
    BMC Ophthalmol; 2020 Sep; 20(1):371. PubMed ID: 32943041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The VEGF Treatment of AMD Switch Study (The vTAS Study).
    Curry B; Bylsma G; Hewitt AW; Verma N
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):481-487. PubMed ID: 29204996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aflibercept for the treatment of diabetic macular edema.
    Harkins KA; Haschke M; Do DV
    Immunotherapy; 2016 May; 8(5):503-10. PubMed ID: 26907516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry.
    Gabrielle PH; Nguyen V; Creuzot-Garcher C; Arnold JJ; Mehta H; Duran MA; Bougamha W; Carreño E; Viola F; Squirrell D; Barthelmes D; Gillies M
    Retina; 2022 Jun; 42(6):1085-1094. PubMed ID: 35174799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
    Holekamp N; Duff SB; Rajput Y; Garmo V
    J Med Econ; 2020 Mar; 23(3):287-296. PubMed ID: 31502893
    [No Abstract]   [Full Text] [Related]  

  • 37. Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey.
    Yilmaz M; Citirik M; Rahmanlar H; Alkan A; Gursoz H
    Rom J Ophthalmol; 2022; 66(4):304-309. PubMed ID: 36589330
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of intravitreal anti-vascular endothelial growth factor injections on corneal endothelium in patients with diabetic macular oedema.
    Chatziralli I; Papadakou P; Dimitriou E; Kazantzis D; Kapsis P; Theodossiadis G; Papathanassiou M; Theodossiadis P
    Cutan Ocul Toxicol; 2021 Jun; 40(2):66-69. PubMed ID: 33599552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re: Korobelnik et al.: Intravitreal aflibercept for diabetic macular edema (Ophthalmology 2014;121:2247-54).
    Hashmonay R; Parikh S
    Ophthalmology; 2015 Jun; 122(6):e37-8. PubMed ID: 26008915
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.